Superluminal Medicines, a Boston-based biotech specializing in AI-powered small molecule drug discovery, has entered a substantial collaboration with pharmaceutical giant Eli Lilly worth up to $1.3 billion. The partnership targets cardiometabolic diseases and obesity by leveraging Superluminal's integrated platform that combines AI, structural biology, and protein dynamics. Lilly gains exclusive rights to develop and commercialize successful compounds, while Superluminal advances its internal drug candidates focused on genetic obesity, exemplifying a dual research and partnership approach.